Business Context and Reporting Period
Kestra Medical Technologies, Ltd. (KMTS) is a commercial-stage medical device company focused on the Cardiac Recovery System platform, anchored by the ASSURE® Wearable Cardioverter Defibrillator (WCD). The company generates revenue primarily through leasing the WCD to patients, with reimbursement from third-party payors including Medicare, Medicaid, and private insurers. This Form 10-Q covers the quarterly period ended July 31, 2026.
Key Financial Metrics
| Metric | Q2 2026 (Three Months Ended July 31) | Q2 2025 (Three Months Ended July 31) |
|---|---|---|
| Revenue | $30.97 million | $19.37 million |
| Gross Profit | $17.50 million | $8.85 million |
| Gross Margin | 56.5% | 45.7% |
| Net Loss | $(44.09) million | $(25.83) million |
| Net Loss Per Share (Basic & Diluted) | $(0.75) | $(0.50) |
| Operating Cash Flow | $(32.30) million | $(26.27) million |
| Cash, Cash Equivalents, and Investments | $244.70 million | $262.20 million (as of April 30, 2026) |
| Long-Term Debt (Net) | $72.50 million | $42.65 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 60% ($11.6 million) year-over-year, driven by a higher number of patients utilizing the ASSURE® WCD.
- Expense Increases: Total operating expenses rose 46% to $55.16 million. Selling, general, and administrative (SG&A) expenses increased 43% due to headcount expansion for commercial growth. Research and development (R&D) expenses increased 70%, partly due to a strategic collaboration with Biobeat Technologies.
- Debt Restructuring: The company entered into a new $200 million senior secured term loan facility (2026 Term Loan) on July 10, 2026. The initial $75 million tranche was used to repay the previous Term Loan 2024, resulting in a $6.3 million loss on extinguishment of debt.
- Warrant Liability: Warrant liabilities associated with the previous debt facility were extinguished, resulting in a $1.62 million gain recorded within the loss on extinguishment of debt.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and investments ($244.7 million as of July 31, 2026) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring net losses as it scales its commercial organization.
- Debt Covenants: The new 2026 Term Loan requires the company to maintain a minimum liquidity of $20 million in cash and cash equivalents. Tranche C ($50 million) is contingent on achieving trailing twelve-month revenue of $150 million.
- Internal Control Material Weaknesses: The company disclosed that its disclosure controls and procedures were not effective as of July 31, 2026. Material weaknesses were identified regarding the control environment, accounting for complex transactions, segregation of duties, and IT general controls. Remediation efforts are underway, including hiring additional accounting and IT personnel.
- Risk Factors: Key risks include the ability to maintain regulatory approvals, reimbursement availability, scaling manufacturing, and the potential need for additional equity or debt financing if operating expenses exceed expectations.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new $20 million minimum liquidity covenant under the 2026 Term Loan.
- Internal Controls: Monitor progress on remediation of material weaknesses in internal controls over financial reporting, specifically regarding IT general controls and segregation of duties.
- Revenue Realization: Assess the sustainability of the 60% revenue growth and the impact of reimbursement rates from Medicare and private payors on gross margins.
- Cash Burn Rate: Review the trajectory of operating cash flow burn ($32.3 million for the quarter) against the $244.7 million cash balance to validate the 12-month liquidity runway.
- Debt Milestones: Track progress toward the $150 million trailing twelve-month revenue threshold required to access the $50 million Tranche C of the new credit facility.